Clinical approaches to vaccination in oncology

Annals of Hematology

Volumn 80, Issue 5, 2001, Pages 255-266

  Renner, C ^a   Kubuschok, B ^a   Trumper L ^a   Pfreundschuh, M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Dendritic cells; Gene transfer; Hybrid cell vaccine; Tumour peptides; Tumour vaccine

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 4; PEPTIDE; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CLINICAL STUDY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEMALE; GENE TRANSFER; HUMAN; HYBRID CELL; IMMUNE STATUS; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; LEUKEMIA; MALE; MELANOMA; NONHODGKIN LYMPHOMA; ONCOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; VACCINATION;

CANCER VACCINES; DRUG DESIGN; HUMANS; IMMUNOTHERAPY, ADOPTIVE;

EID: 0034982046     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770100324     Document Type: Review

References (96)

1. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors
2. Immunomodulation of cancer: Potential use of selectively replicating agents
3. h epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen
4. Danger: The view from the bottom of the cliff
5. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction
6. Clinical applications of dendritic cell cancer vaccines
7. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma
8. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
9. Counterpoint. Cancer vaccines: Single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine
10. Expression of MAGE genes in primary and metastatic cutaneous melanoma
11. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
12. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
13. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma
14. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library
15. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
16. Discrimination and dialogue in the immune system
17. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigius)
18. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
19. T cell memory
20. Replicative senescence of T cells: Does the Hayflick Limit lead to immune exhaustion?
21. Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems
22. Cellular peptide composition governed by major histocompatibility complex class I molecules
23. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
24. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
25. Monitoring specific T cell responses to melanoma vaccines: ELISPOT, Tetramers and beyond
26. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
27. Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin
28. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
29. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
30. Dendritic cells: Multi-lineal and multi-functional
31. The regressing thin malignant melanoma: A distinctive lesion with metastatic potential
32. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells
33. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells
34. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trial
35. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine
36. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
37. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector
38. T-cell epitope mapping by flow cytometry
39. Gene-modified spontaneous Epstein-Barr-virus transformed lymphoblastoid cell lines as autologous cancer vaccine: p21 ras oncogene as a model
40. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
41. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
42. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
43. Clonal deletion of thymocytes as a tumor escape mechanism
44. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
45. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection
46. Idiotypic protein-pulsed dendritic cell vaccination in multiple
47. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells
48. Spontaneous regression of metastatic renal cancer. Case report and literature review
49. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy
50. An HLA-A2 polyepitope vaccine for melanoma immunotherapy
51. Controlled trial of active immunotherapy in management of stage IIB malignant melanoma
52. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells
53. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
54. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies
55. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
56. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-γ, IL-4, IL-6, or TNF-α
57. Design and evaluation of antigen-specific vaccination strategies against cancer
58. Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells
59. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β-converting enzyme cDNA
60. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
61. Inducing autoimmune disease to treat cancer
62. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
63. Tumour vaccines: A new immunotherapeutic approach in oncology
64. Gene therapy for cancer: What have we done and where are we going?
65. Human neoplasms elicit multiple specific immune responses in the autologous host
66. Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials
67. Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery
68. Quantitation of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT assay and chromium-release assay: A four-centre comparative trial
69. Effect of preexisting cytotoxic T lymphocytes on therapeutic vaccines
70. Th1/Th2 balance in cancer, transplantation and pregnancy
71. Antibody to molecularly defined antigen confined to a tumor cell surface
72. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
73. Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes
74. Cell-based vaccination against melanoma - Background, preliminary results, and perspective
75. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay
76. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
77. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination
78. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
79. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
80. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction
81. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
82. Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma
83. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
84. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
85. Tumor immunotherapy by vaccination with cytokine gene transfected cells
86. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans
87. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4
88. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
89. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells: Monitoring the humoral immune response
90. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
91. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
92. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
93. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
94. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia
95. Alterations in T cell receptor and signal transduction molecules in melanoma patients
96. Localization dose and time of antigens determine immune reactivity